Lakefront Biotherapeutics reported EUR48.75M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
argenx SE USD 1.24B 213M Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
Genmab DKK 748M 77M Jun/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
GRIFOLS EUR 1.65B 101M Sep/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Incyte USD 5.64B 4.67B Sep/2026
Merck EUR 4.97B 630M Sep/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Novartis USD 9.88B 325M Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 10.51B 598M Sep/2026
UCB EUR 2.96B 196M Dec/2025
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026